Topiramate add-on for drug-resistant partial epilepsy

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2008, Pages

  Jette, Nathalie ^a   Hemming, Karla ^b   Hutton, Jane L ^b   Marson, Anthony G ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF WARWICK   (United Kingdom)

^c Lower Lane   (United Kingdom)

Author keywords

*Therapeutic use ; Anticonvulsants *therapeutic use ; Drug resistance; Epilepsies, Partial *drug therapy ; Fructose analogs derivatives; Humans; Randomized Controlled Trials as Topic; Treatment failure

Indexed keywords

PLACEBO; TOPIRAMATE;

ATAXIA; CLINICAL TRIAL; COCHRANE LIBRARY; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOCAL EPILEPSY; HUMAN; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; REVIEW; RISK FACTOR; SEIZURE; SOMNOLENCE; SYSTEMATIC REVIEW; THOUGHT DISORDER; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 55049123413     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD001417.pub2     Document Type: Review

References (92)

1. Ben-Menachem 1996 {published data only} Ben-Menachem E, Dam M, Henriksen O, Schmidt D. Double-blind, placebo-controlled trial of 800 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 1995;Vol. 36:S150.
2. Ben-Menachem E, Dam M, Mikkelsen M, Engelskjon T, Henriksen O, Johannessen S, et al.Topiramate add-on treatment in patients with intractable partial epilepsy: amulticenter study. Epilepsia. 1993; Vol. 34:109.
3. * Ben-Menachem E, Henriksen O, Dam M, Mikkelsen M, Schmidt D, Reid S, et al.Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 1996; Vol. 37, issue 6:539-43.
4. Martinez-Lage J, Ben-Menachem E, Shorvon SD, Weber M. Double-blind, placebo-controlled trial of 400 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 1995;Vol. 36:S149-50.
5. Ostergard L, Dam M, Mikkelsen M. Topiramate as add-on therapy in refractory partial epilepsy. Epilepsia. 1992; Vol. 33:105.
6. Elterman 1999 {published data only} * Elterman RD, Glauser TA, Wyllie E, Reife R, Wu SC, Pledger G, et al.A double-blind, randomized trial of topiramate as adjunctive therapy for partial-onset seizures in children. Neurology 1999;52:1338-44.
7. Faught 1996 {published data only} Faught E, Wilder BJ, Ramsay RE. Topiramate dose-ranging trial in refractory partial epilepsy. Epilepsia. 1995; Vol. 36:33.
8. * Faught E, Wilder BJ, Ramsay RE, Reife RA, Kramer LD, Pledger GW, et al.Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
9. Guberman 2002 {published data only} * Guberman A, Neto W, Gassmann-Mayer C, the EPAJ-119 Study Group. Low-Dose topiramate in adults with treatment-resistant partial-onset seizures. Acta Neurol Scand 2002;106:183-189.
10. Guberman A, Neto W, Gassmann-Mayer C and Topiramate EPAJ-119 Study Group. Efficacy of 200 mg/day topiramate in treatment-resistant partial seizures when added to an enzyme-inducing antiepileptic drug (AED). Epilepsia. 2001; Vol. 42:179-80.
11. Neto W, Gassmann-Mayer C and the Topiramate EPAJ-119 study group. Efficacy and tolerability of 200 mg/day topiramate in a placebo-controlled comparison of titration rates. Epilepsia. 2000;Vol. 41:35.
12. Van Oene J, Neto W, Nilsson J, Hamilton G, Baeten B, Schreiner A, et al. Weight reduction during topiramate treatment of partial seizures. Epilepsia. 2002; Vol. 43:152.
13. Korean 1999 {published data only} * Korean Topiramate Study Group. Topiramate in medically intractable partial epilepsies: double-blind placebo-controlled randomized parallel group trial. Epilepsia 1999;40(12):1767-74.
14. Lee BI. Double-blind placebo-controlled randomized clinical trial of topiramate add-on therapy inmedically intractable partial epilepsies. Korean Neurol Assoc 1998;16:809-819.
15. Privitera 1996 {published data only} Privitera M, Fincham R, Penry JK. Dose-ranging trial with higher doses of topiramate in patients with resistant partial seizures. Epilepsia. 1995; Vol. 36:33.
16. * Privitera M, Fincham R, Pnery J, Reife R, Kramer L, Pledger G, et al.Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1,000-mg daily dosages. Neurology 1996;46:1678-83.
17. Rosenfeld 1996 {unpublished data only} * Rosenfeld W, Abou-Khalil B, Reife R, Hegadus R, Pledger G, and the Topiramate YF/YG Study Group. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazepine or phenytoin for partial-onset seizures. Epilepsia. 1996; Vol. 37, issue Suppl 5:153.
18. Sharief 1996 {published data only} * Sharief M, Viteri C, Ben-Menachem E, Weber M, Reife R, Pledger G, et al.Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy. Epilepsy Research 1996;25:217-24.
19. Sharief MK, Sander JW, Patsalos PN, Shorvon SD. Adjuvant topiramate treatment in intractable partial epilepsy. Epilepsia. 1993; Vol. 6:41.
20. Tassinari 1996 {published data only} Tassinari C, Chauvel P, Chodkiewicz J, Shorvon SD, Henriksen O, Dam M, et al.Double-blind, placebo-controlled trial of 600 mg/day topiramate as add-on therapy in patients with refractory partial epilepsy. Epilepsia. 1995; Vol. suppl. 3:S150.
21. * Tassinari CA, Michelucci R, Chauvel P, Chodkiewicz J, Shorvon S, Henriksen O, et al.Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia 1996;37(8):763-8.
22. Yen 2000 {published data only} * Yen DJ, Yu HY, Guo YC, Chen C, Yiu CH, Su MS. A double-blind, placebo-controlled study of topiramate in adult patients with refractory partial epilepsy. Epilepsia 2000;41(9):1162-6.
23. Aldenkamp 1999 {published data only} Aldenkamp AP, Baker G, Mulder OG, Chadwick D, Cooper P, De Haan GJ, et al.A randomized observer-blind clinical study comparing the cognitive effects of topiramate versus valproate in a first-line add-on design. Epilepsia. 1999; Vol. 40, issue suppl. 2:94.
24. Aldenkamp 2000 {published data only} Aldenkamp AP, Baker G, Mulder OG, Chadwick D, Cooper P, Doelman J, et al.A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia 2000;41(9):1167-78.
25. Arroyo 2003 {published data only} Arroyo S, Squires L, Twyman RE, Wang S. Topiramate as first-line therapy in newly diagnosed epilepsy characterized by partial-onset or primary generalized tonic-clonic seizures. Epilepsia. 2003; Vol. 44, issue Suppl. 8:42.
26. Arroyo 2005 {published data only} Arroyo S, Dodson WE, Privitera MD, Glauser TA, Naritoku DK, Dlugo DJ, et al.Randomized dose-controlled study of topiramate as first-line therapy in epilepsy. Acta Neurologica Scandinavica. 2005; Vol. 112, issue 4:214-22.
27. Barrera 2003 {published data only} Barrera MN, Arroyo S, Squires L, Wang S, Jacobs D. Topiramate effective as first line therapy in children/adolescents with newly diagnosed epilepsy. Epilepsia. 2003; Vol. 44, issue suppl. 8:78.
28. Ben-Menachem 1997 {published data only} Ben-Menachem E, The Topiramate YTC-E Study Group. A double-blind trial of topiramate in patients with generalized tonic-clonic seizures of non-focal origin. Epilepsia. 1997; Vol. 38, issue Suppl 3:60.
29. Ben-Menachem 2005 {published data only} Ben-Menachem E, Privitera MD, Neto W, Wu SC. Response to topiramate (TPM), carbamazepine (CBZ) or valproate (VPA) by seizure type in newly diagnosed epilepsy. Epilepsia. 2005; Vol. 46, issue 6: 274-5.
30. Bialer 2002 {published data only} Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Research. 2002; Vol. 51, issue 1-2:31-71.
31. Bialer 2004 {published data only} Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Perucca E, Tomson T. Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference (EILATVII).. Epilepsy Research. 2004; Vol. 61, issue 1-3:1-48.
32. Biton 1996 {published data only} * Biton V, Montouris G, Edwards K, Kamin M. Comparison of two upward titration rates in initiation of therapy with topiramate. Epilepsia. 1996; Vol. 37, issue suppl. 4:5.
33. Biton 1999 {published data only} Biton V, Montouris GD, Ritter F, Riviello JJ, Reife R, Lim P, et al.A randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Neurology 1999;52:1330-7.
34. Biton 2001 {published data only} Biton V, Edwards KR, Montouris GD, Sackellares JC, Harden CL, Kamin M. Topiramate titration and tolerability. Annals of Pharmacotherapy. 2001; Vol. 35, issue 2:173-9.
35. Blum 2006 {published data only} Blum D, Meador K, Biton V, Fakhoury T, Shneker B, Chung S, et al.Cognitive effects of lamotrigine compared with topiramate in patients with epilepsy. Neurology 2006;67:400- 6.
36. Brodie 1997 {published data only} Brodie MJ, The Topiramate YTC-E Study Group. Topiramate as long-term therapy in generalized tonic-clonic seizures of non-focal origin. Epilepsia. 1997; Vol. 38, issue Suppl 3:60.
37. Christensen 2001 {published data only} Christensen J, Poulsen JH, Andreasen F, Dam M. Topiramate addon treatment in refractory epilepsy patients: a randomized concentration-controlled clinical trial. Epilepsia. 2001; Vol. 42, issue Suppl 7:178.
38. Christensen 2003 {published data only} Christensen J, Andreasen F, Poulsen JH, Dam M. Randomized, concentration-controlled trail of topiramate in refractory focal epilepsy. Neurology 2003;61:1210- 1218.
39. Coles 1999 {published data only} Coles H, Baker G, O'Donoghue M. Seizure severity in patients with partial onset (POS) or primary generalised tonic-clonic (PGTC) seizures following treatment with topiramate. A comparison of two different methodologies in a randomised controlled trial. Epilepsia. 1999; Vol. 40, issue suppl. 2:285.
40. Coppola 2002 {published data only} Coppola G, Caliendo G, Veggiotti P, Romeo A, Tortorella G, De Marco P, et al.Topiramate as as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study. Epilepsy. 2002; Vol. 51, issue 1-2:147-53.
41. Dlugos 2003 {published data only} Dlugos DJ, Squires L, Wang S. Neurobehavioral adverse events (AES) with topiramate monotherapy in children and adolescents. Epilepsia. Vol. 44; Vol. suppl. 9, issue 2003.
42. Edwards 1997 {published data only} Edwards K, Norton J, Potter D. Assessment of efficacy and tolerability of topiramate in slow versur rapid titration. Epilepsia. 1997; Vol. 38, issue Suppl 3:59.
43. Edwards 2004 {published data only} Edwards J, Privitera M, Neto W, Wu SC. Topiramate (TPM) vs Carbamazepine (CBZ) and valproate (VPA) in newly diagnosed epilepsy: effectiveness according to seizure type. Epilepsia. 2004; Vol. 45, issue 7:S127.
44. Faught 2003 {published data only} Faught E, Squires L, Want S, Thienel U. Tolerability and safety on topiramate as first line monotherapy in 1,000+ epilepsy patients. Epilepsia. 2003; Vol. Vol. 44, issue Suppl. 9:100.
45. Fritz 2005 {published data only} Fritz N, Glogau S, Hoffmann J, Rademacher M, Elger CE, Helmstaedter C. Efficacy and cognitive side effects of tiagabine and topiramate in patients with epilepsy. Epilepsy & Behavior. 2005; Vol. 6, issue 3:373-81.
46. Gilliam 2003 {published data only} Gilliam FG, Veloso F, Bomhof MA, Gazda SK, Biton V, Ter Bruggen JP, et al.A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology. 2003; Vol. 60, issue 2:196-202.
47. Glauser 2000 {published data only} Glauser TA, Levisohn PM, Ritter F, Sachdeo RC. Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial. Topiramate YL Study Group. Epilepsia. 2000; Vol. 41, issue 1:S86-90.
48. Isojarvi 2005 {published data only} Isojarvi JI, Kerls SP, Caldwell PT, Hammer AE, Messenheimer JA. Double-blind evaluation of the cognitive effects of lamotrigine versus topiramate adjunctive therapy. Epilepsia. 2005; Vol. 46, issue 8:176.
49. Kazibutowska 2000 {published data only} Kazibutowska Z, Stelmach-Wawrzyczek M. Efficacy of therapy with new antiepileptic drugs (tiagabine, gabapentin, topiramate) in drug-resistant epilepsy. Epilepsia. 2000; Vol. 41, issue Suppl Florence:38.
50. Kerls 2006 {published data only} Kerls SP, Hammer AE, Kustra RP, Chung S. Evaluation of the Cognitive Effects of Lamotrigine Versus Topiramate Adjunctive Therapy in Older Adult Patients with Epilepsy. Epilepsia. 2006; Vol. 47, issue 4:162.
51. Levisohn 2003 {published data only} Levisohn PM, Holland KD, Hulihan JF, Fisher AC. Topiramate versus valproate in patients with juvenile myoclonic epilepsy. Epilepsia. 2003; Vol. 44, issue suppl. 9:267.
52. Lim 2004 {published data only} Kyunghwa Lim. Heung Dong Kim and Korean BRE Study Group (Epilepsy Center. Sanggye Park Hospital and Pediatrics College of Medicine Yonsei University. Seoul Korea). Low-dose topiramate compared with carbamazepine in treating benign rolandic epilepsy. Epilepsia. 2004; Vol. 45, issue 7:322.
53. Majkowski 2002 {published data only} J. Majkowski, A. Petrukhin, P. Rajna, M. Moran, W. Neto, R. Wapenaar et al. and the Top-INT-19 Investigators group. Time-course of adverse events (AE) during topiramate (TPM) in carbamazepine-refractory partial onset epllepsy. Epilepsia. 2002; Vol. 43:151.
54. Marson 2007a {published data only} Marson A, Smith D, Tudur Smith C, Williamson P, Jacoby A, Chadwick D. Carbamazepine versus gabapentin, lamotrigine, oxcarbazepine and topiramate for epilepsy: results from arm A of the SANAD trial. Epilepsia. 2006; Vol. 47:272.
55. * Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW et al. and SANAD Study Group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomized controlled trial.. Lancet 2007;369(9566):1000-1015.
56. Marson 2007b {published data only} * Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW et al. and the SANAD study group. the SANAD study of effectiveness of valproate, lamotrigine or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007; Vol. 369, issue 9566:1016-1026.
57. Smith D, Marson A, Tudur Smith C, William P, Jacoby A, Chadwick D. Valproate versus lamotrigine and topiramate for epilepsy: results from arm B of the SANAD trial. Epilepsia. 2006; Vol. 47:274.
58. Martin 2002 {published data only} Martin M, Galiano ML, Fernandez-Bullido Y. Tlagabine and topiramate in vigahatrine substitution in epilepsy patients. Epilepsia. 2002; Vol. 43, issue 8:126.
59. Meador 2003 {published data only} Loring D, Kamin M, Karim R. Topiramate or valproate added to carbamazepine in adults with epilepsy: effects on subjective and objective measures of cognitive function. Epilepsia. 2000; Vol. 41:113.
60. * Meador, K.J, Loring, D.W, J.F, Kamin, M, Karim. R. Differential cognitive and behavioral effects of topiramate and valproate. Neurology. 2003; Vol. 60, issue 9:1483-8.
61. Mehta 2001 {published data only} Mehta S, Pryor FM, Rowan AJ, Uthman B, Ramsay RE. Tolerability and efficacy of topiramate in older patients. Epilepsia. 2001; Vol. 42, issue Suppl 7:143.
62. Mehta 2002 {published data only} Mehta S, Pryor FM, Kraut L, Hulihan J, Ramsey RE. Efficacy and Tolerability of Topiramate in the Elderly Population. Epilepsia. 2002; Vol. 43, issue 7:165.
63. Michelucci 1995 {published data only} Michelucci R, Passarelli D, Tassinari CA. Topiramate in the treatment of refractory partial epilepsy: a double-blind study with long-term follow-up. Epilepsia. 1995; Vol. 36, issue suppl. 3:S150.
64. Michelucci 1996 {published data only} Michelucci R, Passarelli D, Tassinari CA. Topiramate in the treatment of refractory epilepsy: a 2 year long-term follow-up. Epilepsia. 1996; Vol. 37, issue suppl. 4:70-1.
65. Montouris 2000 {published data only} Montouris GD, Biton V, Rosenfeld WE. Nonfocal generalized tonicclonic seizures: response during long-term topiramate treatment. Topiramate YTC/YTCE study group. Epilepsia. 2000; Vol. 41, issue 1:S77-81.
66. Morgenroth 2003 {published data only} Morgenroth L, Pryor FM, Ramsay E, Hulihan JF. Topiramate monotherapy: interim blinded data from a study in elderly patients. Epilepsia. 2003; Vol. 44, issue suppl 9:268.
67. Naritoku 2005 {published data only} Naritoku DK, Hulihan JF, Schwarzman LK, Kamin M, Olson WH. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. The Annals of Pharmacother. 2005; Vol. 39, issue 3:418-23.
68. Privitera 2000 {published data only} Privitera MD, Brodie MJ, Neto W, Want S, the Topiramate EPMN-105 Study Group. Monotherapy in newly diagnosed epilepsy: topiramate vs investigator choice of carbamazepine or valproate. Epilepsia. 2000; Vol. 41, issue Suppl Florence: 138.
69. Privitera 2003 {published data only} Privitera MD, Arroyo S, Squires L, Wang S, Twyman R. 100 mg/day topiramate as the initial target dose in newly diagnosed epilepsy. Epilepsia. 2003; Vol. 44, issue suppl. 9:270.
70. Privitera MD, Brodie MJ, Mattson RH, Chadwick DW, Neto W, Wang S. Topiramate, carbamazepine and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurologica Scandinavica. 2003; Vol. 107, issue 3:165-75.
71. Pryor 2002 {published data only} Pryor F, Ramsay RE, Kraut L, Hulihan J. Interim safety analysis from a study of topiramate in the treatment of seizures in elderly patient. Epilepsia. 2002; Vol. 43, issue suppl. 8:183.
72. Ramsay 2005 {published data only} Ramsay RE, Rowan AJ, Spitz M, Uthman B, Sirven JI, Fredrick TE, et al. Topiramate (TPM) in older adults with partial-onset seizures: a double-blind, dose-comparison study. Epilepsia. 2005; Vol. 46, issue 6:114.
73. Rho 2003 {published data only} Rho JM, Arroyo S, Squires L, Wang S, Jacobs D. Topiramate as first-line therapy: findings from children/adolescents with newly diagnosed epilepsy. Epilepsia. 2003; Vol. 44, issue suppl. 9:93.
74. Ritter 2000 {published data only} Ritter F, Glauser T, Dlterman R, Wyllie E, and the Topiramate YP Study Group. Effectiveness, Tolerability, and Safety of Topiramate in Children with Partial-Onset Seizures. Epilepsia 2000;41(1):S82-S85.
75. Sander 2003 {published data only} Sander JWAS, Arroyo S, Privitera M, Squires L, Wang S, Twyman R. Topiramate in newly diagnosed epilepsy: 100 mg/day as initial target dose. Epilepsia. 2003; Vol. 44, issue Suppl. 8:82.
76. Shields 2004 {unpublished data only} Shields WD. Phase III randomized, double-blind, placebo-controlled study of oral topiramate for Lennox-Gastaut syndrome.. www.clinicaltrials.gov/ct/show/NCT00004776 2004.
77. Walker 1996 {published data only} Walker MC, Sharief MK, Sander JWAS, Patsalos PN, Shorvon SD. Double-blind placebo-controlled trial of topiramate in refractory partial epilepsy with open-label concentration. Epilepsia. 1996; Vol. 37, issue suppl. 4:80.
78. Wang 2001 {published data only} * Wang Y, Zhou D, Pauli E, Stefan H. Topiramate on ictal seizure semiology: a quantitative, randomized, low and medium dose-controlled study. Epilepsy Research. 2001; Vol. 46, issue 3:271-7.
79. Wang 2002 {published data only} Wang Y, Zhou D, Wang B, Kirchner A, Hopp P, Kerling F, et al.Clinical effects of topiramate against secondarily generalized tonic-clonic seizures. Epilepsy Res 2002;49(2):121-30.
80. Wheless 2003 {published data only} Wheless JW, Arroyo S, Squires L, Twyman RE, Wang S. Topiramate as first-line therapy in newly diagnosed epilepsy characterized by partial onset or primary generalized tonic-clonic seizures. Epilepsia. 2003; Vol. 44, issue Suppl. 9:273.
81. Wheless 2004 {published data only} Wheless JW, Neto W, Wang S. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in children with newly diagnosed epilepsy. Journal of Child Neurology. 2004; Vol. 19, issue 2:135-41.
82. Kerr 2005 {published data only} * Kerr M. A randomized placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability. Epilepsia. 2004; Vol. 45, issue suppl. 3:150.
83. Kerr MP, Baker GA, Brodie MJ. A randomized double-blind, placebo-controlled trial of topiramate in adults with epilepsy and intellectual disability: impact on seizures, severity, and quality of life. Epilepsia Behavior. 2005; Vol. 7, issue 3:472-80.
84. Anonymous {published data only} Anonymous. A randomized, double-blind, placebo-controlled, fixed dose-ranging study to assess the safety, tolerability, and efficacy of topiramate oral liquid and sprinkle formulations as an adjunct to concurrent anticonvulsant therapy for infants (1-23 months of age, inclusive) with refractory, partial-onset seizures, with open-label extension.
85. Brown 1993 Brown SD, Wolf HH, Swinyard EA, et al. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia 1993; Vol. 34, issue Suppl 2:122.
86. Cockerell 1995 Cockerell OC, Johnson AL, Sander JW, Hart YM, Shorvon SD. Remission of epilepsy: results fromthe national general practice study of epilepsy. Lancet 1995;346:140-4.
87. Coulter 1993 Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993; Vol. 34, issue Suppl 2:123.
88. Hauser 1975 Hauser WA, Kurtland LT. The epidemiology of epilepsy in Rochester, Minnesota, 1935 through 1967. Epilepsia 1975;16:1-66.
89. McCullagh 1989 McCullagh P, Nelder JA. Generalized linearmodels. 2nd Edition. London: Chapman and Hall, 1989.
90. Reynolds 1981 Reynolds EH, Shorvon SD, Galbraith AW. Phenytoin for epilepsy: a long term prospective study, assisted by serum level monitoring in previously untreated patients. Epilepsia 1981;22:475.
91. Marson 1996 Marson AG, Kadir ZA, Chadwick DW. New antiepileptic drugs; a systematic review of their efficacy and tolerability. British Medical Journal 1996;313:1169-74.
92. Marson 1997 Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs; a systematic review of their efficacy and tolerability. Epilepsia 1997;38:859-80.